Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver
disease, which is rapidly becoming a worldwide public health problem. It is more common in
the military and Veteran population compared to the general US population. NASH may progress
to end-stage liver disease and primary liver cancer, and hence there is critical need for
effective treatment. The goal of this clinical trial is to test whether low dose thyroid
hormone administered to Veterans diagnosed with NASH can be an effective therapy mediated by
improvement in breaking down fat in the mitochondria. The study will be conducted in two
stages, the first stage is for proof of concept to be followed by interim analysis. If the
interim analysis supports the merit for continuing the study, the clinical trial will proceed
to stage 2 for continuation. This study will provide new information and strategies for
treatment of NASH using low dose thyroid hormone that will be highly relevant and impactful
to the health of the Veteran population.